Your session is about to expire
← Back to Search
Fenfluramine for Infantile Spasms
Study Summary
This trial will test if fenfluramine is an effective treatment for children with infantile spasms who have not responded to other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 262 Patients • NCT02682927Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My child is between 1 and 3 years old.You started and kept on a ketogenic diet within 3 months before the screening.My child has been diagnosed with infantile spasms.I had a vagal nerve stimulator implanted within the last 14 days.You have used any products containing cannabinoids in the two weeks before screening.I haven't started or changed the dose of my infantile spasms treatment in the last 14 days.My seizures have not stopped despite treatment with ACTH and vigabatrin.I have a serious heart condition.
- Group 1: Fenfluramine treatment
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the trial have any age restrictions, specifically for individuals over 35?
"This trial is intended for those aged between 1 year and 3 years old. There are 11 separate trials available to minors, while 9 other studies target people over 65."
Do I meet the qualifications to be included in this research?
"Eligibility requirements state that the accepted patients must have infantile spasms and be between 12 months and 36 months of age. This clinical trial is looking to recruit approximately 10 individuals who meet these criteria."
Are there any risks associated with utilizing Fenfluramine as a therapeutic option?
"The safety profile of fenfuramine was rated a 2 out of 3 points due to the fact that only preliminary evidence exists regarding its efficacy, which is standard for Phase 2 trials."
What have prior investigations demonstrated about Fenfluramine as a form of treatment?
"Presently, there are 5 ongoing studies into the efficacy of Fenfluramine with 4 in Phase 3. Most trials occur in Boston, MA; however, 188 clinical trial sites exist throughout the country offering this treatment option."
Could you provide a numerical estimate of the participants in this trial?
"This research endeavour is no longer accepting patients, having been first posted on September 1st 2023 and last modified four months later. If you are still seeking a medical study to participate in, there currently exist 13 trials involving infantile spasms as well as 5 clinical tests researching the efficacy of Fenfluramine treatment."
Does this research represent a unique approach?
"To-date, 5 ongoing studies of Fenfluramine treatment are being conducted in 57 cities and 15 nations. The pioneering research was done by Zogenix International Limited, Inc., a subdivision of Zogenix, Inc.. This trial had 296 participants and has since achieved Phase 3 drug approval status; 7 other investigations have concluded their experiments since 2017."
Are there any open enrollment requirements for this research project?
"This research endeavour is no longer recruiting participants, as it was first posted on September 1st 2023 and last updated April 12th of the same year. If you are still seeking active trials, 13 studies in total are currently enrolling those with infantile spasms while 5 more clinical trials require Fenfluramine treatment candidates."
Share this study with friends
Copy Link
Messenger